

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	Maggi et al.	Confirmation No.:	3801
SERIAL NUMBER:	10/507,344	EXAMINER :	Hasan Syed Ahmed
FILING DATE:	September 10, 2004	ART UNIT :	1615
FOR:	THERAPEUTIC SYSTEM FOR THE CONTROLLED RELEASE OF ACTIVE INGREDIENTS		

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Supplemental Information Disclosure Statement is being filed after the mailing date of the first Office Action, but before the mailing date of either a final action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311. The fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) is enclosed.

The following items of information contained in this Information Disclosure statement were first cited in the corresponding Japanese Examiner's Report for the related published Japanese Patent Application No. 2003-574172, which was communicated to Applicants' U.S. attorneys on October 22, 2009. This communication was not received by any individual designated in 1.56(c) more than thirty days prior to the filing of the Supplemental Information Disclosure Statement under 37 C.F.R. §1.704(d).

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.


APPLICANT: Maggi et al.
U.S.S.N.: 10/507,344

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 28069-602N01US.

Respectfully submitted,



David E. Johnson, Reg. No. 41,874
Erica R. Carlson, Reg. No. 58,032
Attorney(s) for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.

Address all written correspondence to

Customer no.: 30623

Tel: (617) 542-6000

Fax: (617) 542-2241

Date: November 17, 2009

4763209v.1